793TiP A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005
Lorusso, D., Mirza, M.R., Martin-Babau, J., Bologna, A., Barretina Ginesta, M.P., Marmé, F., Wampfler, J., Cibula, D., Zhu, J., Hasegawa, K., Samouëlian, V., Lee, J-Y., Casarotto, F.C., Antill, Y., Lightfoot, M., Herzog, T.J., Woodhouse, K., Cui, Y., Slomovitz, B.M., Monk, B.J.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article